Found: 75
Select item for more details and to access through your institution.
Alirocumab: Pediatric First Approval.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Correction: Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Add or switch to systemics and biologics where topical paediatric hidradenitis suppurativa therapy fails.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 6, p. 211, doi. 10.1007/s40267-024-01076-7
- By:
- Publication type:
- Article
Suspect cutaneous lupus erythematous in older patients with photosensitive rash.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 6, p. 216, doi. 10.1007/s40267-024-01080-x
- By:
- Publication type:
- Article
Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo.
- Published in:
- Drugs, 2024, v. 84, n. 5, p. 579, doi. 10.1007/s40265-024-02027-2
- By:
- Publication type:
- Article
Danicopan: First Approval.
- Published in:
- Drugs, 2024, v. 84, n. 5, p. 613, doi. 10.1007/s40265-024-02023-6
- By:
- Publication type:
- Article
Aim to alleviate alopecia areata with newly available agents.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 5, p. 181, doi. 10.1007/s40267-024-01069-6
- By:
- Publication type:
- Article
Dietary supplements may boost memory, but more evidence is required.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 5, p. 185, doi. 10.1007/s40267-024-01070-z
- By:
- Publication type:
- Article
Determine and remove the drug trigger, usually antibiotics, that causes acute generalised exanthematous pustulosis.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 4, p. 141, doi. 10.1007/s40267-024-01064-x
- By:
- Publication type:
- Article
Impact of a Mock OSCE on Student Confidence in Applying the Pharmacists' Patient Care Process.
- Published in:
- Pharmacy, 2024, v. 12, n. 2, p. 54, doi. 10.3390/pharmacy12020054
- By:
- Publication type:
- Article
Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Sparsentan in immunoglobulin A nephropathy: a profile of its use.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 3, p. 101, doi. 10.1007/s40267-024-01058-9
- By:
- Publication type:
- Article
Get on top of gout with a fresh look at treatment options.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 3, p. 115, doi. 10.1007/s40267-024-01063-y
- By:
- Publication type:
- Article
Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2− Breast Cancer.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 2, p. 289, doi. 10.1007/s11523-024-01036-1
- By:
- Publication type:
- Article
Lumasiran: A Review in Primary Hyperoxaluria Type 1.
- Published in:
- Drugs, 2024, v. 84, n. 2, p. 219, doi. 10.1007/s40265-023-01987-1
- By:
- Publication type:
- Article
Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 6, p. 981, doi. 10.1007/s11523-023-00998-y
- By:
- Publication type:
- Article
Avacincaptad Pegol: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 15, p. 1447, doi. 10.1007/s40265-023-01948-8
- By:
- Publication type:
- Article
Prescribe colchicine with care and be aware of colchicine drug interactions.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 10, p. 348, doi. 10.1007/s40267-023-01024-x
- By:
- Publication type:
- Article
Manage truncal acne and scarring the same as for facial acne, but more trunk-specific therapies are warranted.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 9, p. 324, doi. 10.1007/s40267-023-01018-9
- By:
- Publication type:
- Article
Manage seborrhoeic dermatitis in older adults with customised regimens that address age-related factors.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 7, p. 232, doi. 10.1007/s40267-023-01004-1
- By:
- Publication type:
- Article
Consider new therapies for the treatment and prevention of Clostridioides difficile infection.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 7, p. 237, doi. 10.1007/s40267-023-01006-z
- By:
- Publication type:
- Article
Ravulizumab: A Review in Generalised Myasthenia Gravis.
- Published in:
- Drugs, 2023, v. 83, n. 8, p. 717, doi. 10.1007/s40265-023-01877-6
- By:
- Publication type:
- Article
Retifanlimab: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 8, p. 731, doi. 10.1007/s40265-023-01884-7
- By:
- Publication type:
- Article
Treat hyperhidrosis with topical therapies first, then dermatological or systemic therapies.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 6, p. 200, doi. 10.1007/s40267-023-00996-0
- By:
- Publication type:
- Article
Risk of falls and fractures does not necessarily preclude the use of antihypertensive medications.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 6, p. 212, doi. 10.1007/s40267-023-00999-x
- By:
- Publication type:
- Article
Keverprazan Hydrochloride: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 7, p. 639, doi. 10.1007/s40265-023-01865-w
- By:
- Publication type:
- Article
The treatment of post-traumatic nightmares requires more attention.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 4, p. 125, doi. 10.1007/s40267-023-00988-0
- By:
- Publication type:
- Article
Treat bladder dysfunction in older patients with established agents, but botulinum toxin type A may have a role.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 4, p. 141, doi. 10.1007/s40267-023-00987-1
- By:
- Publication type:
- Article
Olutasidenib: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 4, p. 341, doi. 10.1007/s40265-023-01844-1
- By:
- Publication type:
- Article
Clozapine is the approved option in treatment-resistant schizophrenia and requires careful management.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 3, p. 107, doi. 10.1007/s40267-023-00982-6
- By:
- Publication type:
- Article
Management of central neuropathic pain involves many drugs but few have proven efficacy.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 1, p. 1, doi. 10.1007/s40267-022-00965-z
- By:
- Publication type:
- Article
Consider cannabinoids as an individual therapeutic trial in nociplastic pain.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 1, p. 13, doi. 10.1007/s40267-022-00954-2
- By:
- Publication type:
- Article
Limit acne damage with lasers and light therapy.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 1, p. 20, doi. 10.1007/s40267-022-00970-2
- By:
- Publication type:
- Article
Opioid misuse in older patients requires careful consideration of many factors.
- Published in:
- Drugs & Therapy Perspectives, 2022, v. 38, n. 12, p. 527, doi. 10.1007/s40267-022-00964-0
- By:
- Publication type:
- Article
Correction to: AVT02: An Adalimumab Biosimilar.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Teclistamab: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 16, p. 1613, doi. 10.1007/s40265-022-01793-1
- By:
- Publication type:
- Article
Approach the prevention of chemotherapy-induced nausea and vomiting in older patients with care.
- Published in:
- Drugs & Therapy Perspectives, 2022, v. 38, n. 11, p. 483, doi. 10.1007/s40267-022-00952-4
- By:
- Publication type:
- Article
11.2: Invited Paper: Study of Green LED Growth for Advanced Display Applications.
- Published in:
- SID Symposium Digest of Technical Papers, 2022, v. 53, p. 124, doi. 10.1002/sdtp.15868
- By:
- Publication type:
- Article
AVT02: An Adalimumab Biosimilar.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 10, p. 875, doi. 10.1007/s40261-022-01196-w
- By:
- Publication type:
- Article
Digital agriculture platforms: Driving data‐enabled agricultural innovation in a world fraught with privacy and security concerns.
- Published in:
- Agronomy Journal, 2022, v. 114, n. 5, p. 2635, doi. 10.1002/agj2.20873
- By:
- Publication type:
- Article
Consider fibromyalgia in older patients with chronic widespread pain.
- Published in:
- Drugs & Therapy Perspectives, 2022, v. 38, n. 9, p. 394, doi. 10.1007/s40267-022-00940-8
- By:
- Publication type:
- Article
Treat psoriasis with traditional and novel topical therapies.
- Published in:
- Drugs & Therapy Perspectives, 2022, v. 38, n. 9, p. 400, doi. 10.1007/s40267-022-00936-4
- By:
- Publication type:
- Article
Mosunetuzumab: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 11, p. 1229, doi. 10.1007/s40265-022-01749-5
- By:
- Publication type:
- Article
Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
- Published in:
- American Journal of Cardiovascular Drugs, 2022, v. 22, n. 4, p. 451, doi. 10.1007/s40256-022-00538-5
- By:
- Publication type:
- Article
Setmelanotide in obesity: a profile of its use.
- Published in:
- Drugs & Therapy Perspectives, 2022, v. 38, n. 7, p. 308, doi. 10.1007/s40267-022-00929-3
- By:
- Publication type:
- Article
Cardiovascular side effects of non-SSRI antidepressants are of concern in high-risk patients.
- Published in:
- Drugs & Therapy Perspectives, 2022, v. 38, n. 7, p. 329, doi. 10.1007/s40267-022-00927-5
- By:
- Publication type:
- Article
Consider using a broad-spectrum sunscreen daily to prevent photoaging.
- Published in:
- Drugs & Therapy Perspectives, 2022, v. 38, n. 6, p. 268, doi. 10.1007/s40267-022-00920-y
- By:
- Publication type:
- Article
Evolving Type 2 diabetes management focuses on clinical outcomes.
- Published in:
- Drugs & Therapy Perspectives, 2022, v. 38, n. 4, p. 165, doi. 10.1007/s40267-022-00903-z
- By:
- Publication type:
- Article
Diagnose and treat constipation- or diarrhoea-predominant irritable bowel syndrome with confidence.
- Published in:
- Drugs & Therapy Perspectives, 2022, v. 38, n. 4, p. 171, doi. 10.1007/s40267-022-00906-w
- By:
- Publication type:
- Article
Maribavir: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 3, p. 335, doi. 10.1007/s40265-022-01677-4
- By:
- Publication type:
- Article